JP2015526499A - 光力学療法における使用のためのピリジノン化合物 - Google Patents
光力学療法における使用のためのピリジノン化合物 Download PDFInfo
- Publication number
- JP2015526499A JP2015526499A JP2015529127A JP2015529127A JP2015526499A JP 2015526499 A JP2015526499 A JP 2015526499A JP 2015529127 A JP2015529127 A JP 2015529127A JP 2015529127 A JP2015529127 A JP 2015529127A JP 2015526499 A JP2015526499 A JP 2015526499A
- Authority
- JP
- Japan
- Prior art keywords
- compound
- formula
- ala
- photodynamic therapy
- mal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002428 photodynamic therapy Methods 0.000 title claims description 57
- 150000005299 pyridinones Chemical class 0.000 title 1
- 150000003839 salts Chemical class 0.000 claims abstract description 19
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims abstract description 12
- 150000001875 compounds Chemical class 0.000 claims description 132
- 206010028980 Neoplasm Diseases 0.000 claims description 23
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 21
- 238000000034 method Methods 0.000 claims description 20
- 201000011510 cancer Diseases 0.000 claims description 14
- 230000002159 abnormal effect Effects 0.000 claims description 13
- 239000003814 drug Substances 0.000 claims description 12
- 238000006243 chemical reaction Methods 0.000 claims description 11
- 238000002405 diagnostic procedure Methods 0.000 claims description 10
- 125000006239 protecting group Chemical group 0.000 claims description 8
- 241001465754 Metazoa Species 0.000 claims description 6
- 230000010261 cell growth Effects 0.000 claims description 6
- 229910052739 hydrogen Inorganic materials 0.000 claims description 6
- 239000002253 acid Substances 0.000 claims description 5
- 230000004663 cell proliferation Effects 0.000 claims description 5
- 239000002537 cosmetic Substances 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 208000002874 Acne Vulgaris Diseases 0.000 claims description 3
- 206010052428 Wound Diseases 0.000 claims description 3
- 208000027418 Wounds and injury Diseases 0.000 claims description 3
- 206010000496 acne Diseases 0.000 claims description 3
- 230000001684 chronic effect Effects 0.000 claims description 3
- 238000005886 esterification reaction Methods 0.000 claims description 3
- 238000000338 in vitro Methods 0.000 claims description 3
- 208000015181 infectious disease Diseases 0.000 claims description 3
- 230000000813 microbial effect Effects 0.000 claims description 3
- 230000001225 therapeutic effect Effects 0.000 claims description 3
- 238000002560 therapeutic procedure Methods 0.000 claims description 3
- 206010061217 Infestation Diseases 0.000 claims description 2
- 208000012868 Overgrowth Diseases 0.000 claims description 2
- 201000004681 Psoriasis Diseases 0.000 claims description 2
- 206010039710 Scleroderma Diseases 0.000 claims description 2
- 210000001185 bone marrow Anatomy 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 230000003090 exacerbative effect Effects 0.000 claims description 2
- 208000032839 leukemia Diseases 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 238000000746 purification Methods 0.000 claims description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 2
- 230000002784 sclerotic effect Effects 0.000 claims description 2
- 208000014617 hemorrhoid Diseases 0.000 claims 1
- 244000045947 parasite Species 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 102100035831 Filensin Human genes 0.000 description 109
- 108010062616 filensin Proteins 0.000 description 109
- 210000004027 cell Anatomy 0.000 description 104
- ZGXJTSGNIOSYLO-UHFFFAOYSA-N 88755TAZ87 Chemical compound NCC(=O)CCC(O)=O ZGXJTSGNIOSYLO-UHFFFAOYSA-N 0.000 description 103
- 229960002749 aminolevulinic acid Drugs 0.000 description 99
- XIYFEESCIBNMIC-UHFFFAOYSA-N 1,2-diethyl-3-hydroxypyridin-4-one Chemical compound CCC1=C(O)C(=O)C=CN1CC XIYFEESCIBNMIC-UHFFFAOYSA-N 0.000 description 81
- YUUAYBAIHCDHHD-UHFFFAOYSA-N methyl 5-aminolevulinate Chemical compound COC(=O)CCC(=O)CN YUUAYBAIHCDHHD-UHFFFAOYSA-N 0.000 description 78
- 229960005033 methyl aminolevulinate Drugs 0.000 description 78
- 229950003776 protoporphyrin Drugs 0.000 description 75
- KSFOVUSSGSKXFI-GAQDCDSVSA-N CC1=C/2NC(\C=C3/N=C(/C=C4\N\C(=C/C5=N/C(=C\2)/C(C=C)=C5C)C(C=C)=C4C)C(C)=C3CCC(O)=O)=C1CCC(O)=O Chemical compound CC1=C/2NC(\C=C3/N=C(/C=C4\N\C(=C/C5=N/C(=C\2)/C(C=C)=C5C)C(C=C)=C4C)C(C)=C3CCC(O)=O)=C1CCC(O)=O KSFOVUSSGSKXFI-GAQDCDSVSA-N 0.000 description 74
- 238000011534 incubation Methods 0.000 description 32
- -1 for example Chemical class 0.000 description 25
- 238000009825 accumulation Methods 0.000 description 21
- 230000003833 cell viability Effects 0.000 description 20
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 20
- 239000003504 photosensitizing agent Substances 0.000 description 19
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 18
- 238000007619 statistical method Methods 0.000 description 16
- 150000003278 haem Chemical class 0.000 description 13
- 206010041823 squamous cell carcinoma Diseases 0.000 description 13
- 230000000694 effects Effects 0.000 description 12
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 12
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 12
- 208000005017 glioblastoma Diseases 0.000 description 9
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 9
- 239000002243 precursor Substances 0.000 description 9
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 9
- 0 CCN(C(*)=C1*)C(*)=C(*)C1=O Chemical compound CCN(C(*)=C1*)C(*)=C(*)C1=O 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 210000002950 fibroblast Anatomy 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 125000000217 alkyl group Chemical group 0.000 description 7
- 238000003556 assay Methods 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- OEUUFNIKLCFNLN-LLVKDONJSA-N chembl432481 Chemical compound OC(=O)[C@@]1(C)CSC(C=2C(=CC(O)=CC=2)O)=N1 OEUUFNIKLCFNLN-LLVKDONJSA-N 0.000 description 7
- 229910052742 iron Inorganic materials 0.000 description 7
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 239000013543 active substance Substances 0.000 description 6
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- 125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- 239000006143 cell culture medium Substances 0.000 description 5
- 150000002500 ions Chemical class 0.000 description 5
- PGSADBUBUOPOJS-UHFFFAOYSA-N neutral red Chemical compound Cl.C1=C(C)C(N)=CC2=NC3=CC(N(C)C)=CC=C3N=C21 PGSADBUBUOPOJS-UHFFFAOYSA-N 0.000 description 5
- 229940002612 prodrug Drugs 0.000 description 5
- 239000000651 prodrug Substances 0.000 description 5
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- YIKYNHJUKRTCJL-UHFFFAOYSA-N Ethyl maltol Chemical compound CCC=1OC=CC(=O)C=1O YIKYNHJUKRTCJL-UHFFFAOYSA-N 0.000 description 4
- 208000000453 Skin Neoplasms Diseases 0.000 description 4
- 230000006696 biosynthetic metabolic pathway Effects 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 150000004032 porphyrins Chemical class 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 description 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 3
- PDXOIPHDAYJEKC-UHFFFAOYSA-N 2-ethyl-1-(2-hydroxyethyl)-3-phenylmethoxypyridin-4-one Chemical compound O=C1C=CN(CCO)C(CC)=C1OCC1=CC=CC=C1 PDXOIPHDAYJEKC-UHFFFAOYSA-N 0.000 description 3
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 3
- GOBFUUKGAGSJCV-UHFFFAOYSA-N 4-oxo-5-(phenylmethoxycarbonylamino)pentanoic acid Chemical compound OC(=O)CCC(=O)CNC(=O)OCC1=CC=CC=C1 GOBFUUKGAGSJCV-UHFFFAOYSA-N 0.000 description 3
- 206010004146 Basal cell carcinoma Diseases 0.000 description 3
- 238000010152 Bonferroni least significant difference Methods 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 238000010162 Tukey test Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 3
- 230000030833 cell death Effects 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 210000003470 mitochondria Anatomy 0.000 description 3
- 238000001543 one-way ANOVA Methods 0.000 description 3
- 239000003642 reactive oxygen metabolite Substances 0.000 description 3
- 210000001626 skin fibroblast Anatomy 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 238000007492 two-way ANOVA Methods 0.000 description 3
- 125000006527 (C1-C5) alkyl group Chemical group 0.000 description 2
- SOPGGYATHODURV-UHFFFAOYSA-N 2-(2-ethyl-3,4-dihydroxypyridin-1-ium-1-yl)ethyl 5-amino-4-oxopentanoate;chloride;hydrochloride Chemical compound Cl.[Cl-].CCC1=C(O)C(O)=CC=[N+]1CCOC(=O)CCC(=O)CN SOPGGYATHODURV-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 206010029098 Neoplasm skin Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 125000006241 alcohol protecting group Chemical group 0.000 description 2
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 2
- 230000022534 cell killing Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 229940093503 ethyl maltol Drugs 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 150000004820 halides Chemical class 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 238000007327 hydrogenolysis reaction Methods 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- QSHWIQZFGQKFMA-UHFFFAOYSA-N porphobilinogen Chemical compound NCC=1NC=C(CCC(O)=O)C=1CC(O)=O QSHWIQZFGQKFMA-UHFFFAOYSA-N 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 150000003141 primary amines Chemical group 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 231100000241 scar Toxicity 0.000 description 2
- 201000000849 skin cancer Diseases 0.000 description 2
- 230000037380 skin damage Effects 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- ILMRJRBKQSSXGY-UHFFFAOYSA-N tert-butyl(dimethyl)silicon Chemical group C[Si](C)C(C)(C)C ILMRJRBKQSSXGY-UHFFFAOYSA-N 0.000 description 2
- 239000012085 test solution Substances 0.000 description 2
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 125000000025 triisopropylsilyl group Chemical group C(C)(C)[Si](C(C)C)(C(C)C)* 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- HCKNRHBSGZMOOF-UHFFFAOYSA-N 1-methoxy-2-methylperoxyethane Chemical compound COCCOOC HCKNRHBSGZMOOF-UHFFFAOYSA-N 0.000 description 1
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- GRTYJFQHNBDOTR-UHFFFAOYSA-N 2-(2-ethyl-4-oxo-3-phenylmethoxypyridin-1-yl)ethyl 4-oxo-5-(phenylmethoxycarbonylamino)pentanoate Chemical compound O=C1C=CN(CCOC(=O)CCC(=O)CNC(=O)OCC=2C=CC=CC=2)C(CC)=C1OCC1=CC=CC=C1 GRTYJFQHNBDOTR-UHFFFAOYSA-N 0.000 description 1
- JMLXKDZVBYFSBK-UHFFFAOYSA-N 2-(hexylamino)-4-oxopentanoic acid Chemical compound CCCCCCNC(C(O)=O)CC(C)=O JMLXKDZVBYFSBK-UHFFFAOYSA-N 0.000 description 1
- 125000003821 2-(trimethylsilyl)ethoxymethyl group Chemical group [H]C([H])([H])[Si](C([H])([H])[H])(C([H])([H])[H])C([H])([H])C(OC([H])([H])[*])([H])[H] 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 101100269551 Arabidopsis thaliana ALA5 gene Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- DCERHCFNWRGHLK-UHFFFAOYSA-N C[Si](C)C Chemical compound C[Si](C)C DCERHCFNWRGHLK-UHFFFAOYSA-N 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- 102000003875 Ferrochelatase Human genes 0.000 description 1
- 108010057394 Ferrochelatase Proteins 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010019851 Hepatotoxicity Diseases 0.000 description 1
- 206010020112 Hirsutism Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 208000005230 Leg Ulcer Diseases 0.000 description 1
- 108090000301 Membrane transport proteins Proteins 0.000 description 1
- 102000003939 Membrane transport proteins Human genes 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 206010067193 Naevus flammeus Diseases 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 208000012641 Pigmentation disease Diseases 0.000 description 1
- 241001303601 Rosacea Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 206010048810 Sebaceous hyperplasia Diseases 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical group [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 206010040799 Skin atrophy Diseases 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 206010043189 Telangiectasia Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 208000009621 actinic keratosis Diseases 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 238000005576 amination reaction Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- HSDAJNMJOMSNEV-UHFFFAOYSA-N benzyl chloroformate Chemical compound ClC(=O)OCC1=CC=CC=C1 HSDAJNMJOMSNEV-UHFFFAOYSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000001851 biosynthetic effect Effects 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 238000013043 cell viability test Methods 0.000 description 1
- 230000007541 cellular toxicity Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000011443 conventional therapy Methods 0.000 description 1
- NIUVHXTXUXOFEB-UHFFFAOYSA-J coproporphyrinogen III(4-) Chemical compound C1C(=C(C=2C)CCC([O-])=O)NC=2CC(=C(C=2C)CCC([O-])=O)NC=2CC(N2)=C(CCC([O-])=O)C(C)=C2CC2=C(C)C(CCC([O-])=O)=C1N2 NIUVHXTXUXOFEB-UHFFFAOYSA-J 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 239000007819 coupling partner Substances 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 201000010251 cutis laxa Diseases 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 208000002026 familial multiple nevi flammei Diseases 0.000 description 1
- 230000008713 feedback mechanism Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000007686 hepatotoxicity Effects 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 238000013427 histology analysis Methods 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 230000003810 hyperpigmentation Effects 0.000 description 1
- 208000000069 hyperpigmentation Diseases 0.000 description 1
- 230000001969 hypertrophic effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000000797 iron chelating agent Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 238000007431 microscopic evaluation Methods 0.000 description 1
- 239000007758 minimum essential medium Substances 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 201000000743 nodular basal cell carcinoma Diseases 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000002186 photoactivation Effects 0.000 description 1
- 230000008832 photodamage Effects 0.000 description 1
- 238000001126 phototherapy Methods 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 201000004700 rosacea Diseases 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 230000036548 skin texture Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000126 substance Chemical group 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 208000009056 telangiectasis Diseases 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- HUHWZXWWOFSFKF-UHFFFAOYSA-N uroporphyrinogen-III Chemical compound C1C(=C(C=2CCC(O)=O)CC(O)=O)NC=2CC(=C(C=2CCC(O)=O)CC(O)=O)NC=2CC(N2)=C(CC(O)=O)C(CCC(=O)O)=C2CC2=C(CCC(O)=O)C(CC(O)=O)=C1N2 HUHWZXWWOFSFKF-UHFFFAOYSA-N 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/69—Two or more oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
- A61K8/4926—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having six membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/81—Preparation or application process involves irradiation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Birds (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyridine Compounds (AREA)
Abstract
Description
本発明は、新規化合物、その調製および使用、ならびにこの化合物を含む組成物に関する。
光力学療法(PDT)は、表在性皮膚悪性病変の治療において日常的に採用される療法であり、一連のさらなる腫瘍型に関して調査中である。PDTの大半の用途は、光感作剤として知られる活性化合物と、感作剤を励起して、活性酸素種を生成するのに適切であるように選択され得る波長の光源の使用とを伴う。これは、光感作剤を選択的に取り込んだか、または局所的に露光されたかのいずれかの任意の組織の破壊をもたらす。
本発明の第1の態様によると、式(I):
R1は、C1−C6アルキル基であり、
R2は、H、またはC1−C6アルキル基であり、
R3は、H、またはC1−C6アルキル基であり、
nは、0〜5の整数である。
R1、R2、R3、およびnは、上に定義される通りであり、
各X−は独立して、一価の対イオンから選択される。
(a)エステル化反応を介して式(II)の化合物を式(III)の化合物と反応させて、式(IV)の化合物を形成するステップであり、以下の反応スキーム:
RPG1およびRPG2は、保護基である。
RPG2は、一級アミン保護基である。一級アミン保護基は、当業者に周知であり、上述のもの等の標準的な教本に列挙されている。
(b2)酸H+X−の存在下で式(IV)の化合物を脱保護し、式(Ia)の塩を得るステップであり、以下の反応スキーム:
(b3)酸H+X−の存在下で式(IV)の化合物を脱保護し、式(Ib)の塩を得るステップであり、以下の反応スキーム:
AP2−18(8)の合成は、ベニルオキシカルボニル保護されたアミノレブリン酸5のCP94類似化合物6とのカップリングを介して達成された。
塩基条件下でALA.HCl(4)(Sigma−Aldrichから入手)をベンジルクロロホルメートに曝露することにより、ALA誘導体5を合成し、ベンジルオキシ保護されたALA5を得た。
1A.ALA誘導体5
ALA誘導体5は、例えば、Neuberger A.et al.,Biochemistry Journal,1956,64,137−145の手順を介して得ることができる既知の化合物である。
1B.CP94類似化合物6
CP94類似化合物6は、以前に公開された手順(Dobbin,P.S.,et al.,J Med Chem,1993.36(17):p.2448−58、Liu,Z.D.et al.,J.Pharm.Pharmacol,1999,51,555−564により調製された。
1C.2−(3−(ベンジルオキシ)−2−エチル−4−オキソピリジン−1(4H)−イル)エチル5−(ベンジルオキシカルボニルアミノ)−4−オキソペンタノアート,7
化合物CP94(3)は、以前に公開された手順(Dobbin,P.S.,et al.,J Med Chem,1993.36(17):p.2448−58)により調製された。以下に示されるように、エチルマルトール(1)を、ベンジル保護し、アミン化し、2を得、水素化分解により脱保護し、CP94(3)を得た。
NB:特に明記しない限り、提示される全てのデータは、各々が各条件の内部反復からなる3つの独立した実験の平均である。
化合物AP2−18(8)が固有の毒性特性を保有するかを確立するために、1000μMの試験溶液を、標準的な細胞培養培地(1%(v/v)のウシ胎児血清(FBS)、200mMのL−グルタミン、200U mL−1のペニシリン、および200μg mL−1のストレプトマイシンを含む最小必須培地(MEM))中で調製した(この研究において試験される最高濃度)。これを、減少した光条件下でMRC−5(ヒト胚性肺線維芽細胞)細胞に適用し、暗所で4時間(皮膚PDT診療所で使用されたものと同等であるため、この時間期間が選択された)放置し、この後、ニュートラルレッド取り込み(NRU)アッセイを用いて、細胞生存率が決定された。ニュートラルレッドは、非生存可能細胞によって行われることが不可能である作用である、生存可能(生存)細胞によって積極的に取り込まれ、選別される不活性色素であり、したがって、取り込まれたニュートラルレッドのレベルは、所与の曝露後に存在する生存可能な細胞の数と正比例する。色素の取り込み後、細胞を溶解し、プレートリーダーを用いて、ニュートラルレッドのレベルを定量化した。
プロトポルフィリンIX(PpIX)蓄積のレベルは、Blake,E.et al.,Photochem Photobiol,2011,87(6),1419−26、Blake,E.et al.,Photochem Photobiol,2010,86(5),1154−60、Curnow,A.et al.,J Environ Pathol Toxicol Oncol,2007,26(2),89−103、およびPye,A.et al.,J Cancer Res Clin Oncol,2008,134(8),841−9に記載される、十分に確立された以前に検証された蛍光に基づくアッセイを用いて監視された。
PpIX誘発PDTの有効性に対するAP2−18(8)の作用を評価するために、同じ3つの細胞型が等モル濃度のALA、ALAおよびCP94(3)、MAL、MAL、およびCP94(3)ならびにAP2−18(8)(前述のように)に曝露され、暗所で4時間インキュベートされた。次に、赤色光(37J/cm2;635±2nm;Aktilite,Galderma,UK)で照射する前に、PpIX蓄積のレベルを前と同じように定量化した。照射直後に残ったPpIXのレベルも確認し、PpIXレベルにおける変化(PpIX光漂白)がパーセントで計算された(図5A、6A、および7A)。次いで、NRUアッセイを用いて(前述の通り)細胞生存率が評価され、これらのデータは、ブランク対照細胞(通常の細胞培地に曝露された)に対して基準化され、生存可能細胞のパーセントとして表される(図5B、6B、および7B)。後に行われた統計分析の結果は、それぞれ、図5C、6C、および7Cに提示される。
ヒト上皮性扁平上皮癌細胞(A431)を、等モル濃度のALA、ALAおよびCP94(3)、MAL、MALおよびCP94(3)、ならびにAP2−18(8)に曝露し(上述の通り)、2、3、または4時間、暗所でインキュベートした。次いで、PpIX蓄積のレベルを測定した。結果は、下の表10に示され、図8A(ALA、ALA、およびCP94(3))、図8B(MAL、MAL、およびCP94(3))、ならびに図8C(CP94(3))に示される。図9は、細胞が化合物(複数可)と共に2時間(図9A(i))、3時間(図9B(i))、および4時間(図9C(i))インキュベートされた後、ALA、ALAおよびCP94(3)、MAL、MALおよびCP94(3)、ならびにAP2−18(8)に曝露された後のヒト上皮性扁平上皮細胞癌細胞(A431)において測定したPpIX蓄積のレベルを比較する。各インキュベーション期間の対応する統計分析の結果は、図9A(ii)(2時間)、図9B(ii)(3時間)、図9C(ii)(4時間)に表される。
Claims (20)
- 式(I):
R1が、C1−C6アルキル基であり、
R2が、H、またはC1−C6アルキル基であり、
R3が、H、またはC1−C6アルキル基であり、
nが、0〜5の整数である。]
の化合物、またはその任意の塩。 - 請求項1に定義される式(I)の化合物、式(Ia)の塩、または式(Ib)の塩:
R1、R2、R3、およびnが、請求項1に定義される通りであり;
各X−が独立して、一価の対イオンから選択される。]
である、請求項1に記載の化合物。 - X−が、Cl−である、請求項2に記載の化合物。
- R1が、エチルであり、R2およびR3が、Hであり、nが、1である、請求項1〜3のいずれか一項に記載の化合物。
- 請求項1〜4のいずれか一項に記載の化合物、および薬学的に許容される担体を含む医薬組成物。
- 請求項1〜4のいずれか一項に記載の化合物の製造方法であって、以下のステップ:
(a)以下の反応スキーム:
R1、R2、R3、およびnが、請求項1に定義される通りであり;
RPG1およびRPG2が、保護基である]
に従って、エステル化反応を介して式(II)の化合物を式(III)の化合物と反応させて、式(IV)の化合物を形成すること、
を含む、方法。 - (b1)以下の反応スキーム:
- (b2)以下の反応スキーム:
- (b3)以下の反応スキーム:
- 療法に使用するための、請求項1〜4のいずれか一項に記載の化合物。
- 光力学療法に使用するための、請求項1〜4のいずれか一項に記載の化合物。
- 前記化合物が、光力学療法による、細胞の異常増殖により生じる、および/または悪化する症状の治療に使用するためのものである、請求項11に記載の化合物。
- 前記化合物が、光力学療法による、癌の治療に使用するためのものである、請求項11に記載の化合物。
- 前記化合物が、光力学療法による、強皮症、硬化性苔癬、乾癬、疣、慢性創傷、座瘡、微生物感染、寄生虫の寄生、または関節リウマチの治療に使用するためのものであるか、または前記化合物が、白血病の治療において、光力学療法による骨髄浄化に使用するためのものである、請求項11に記載の化合物。
- 美容目的のための光力学治療における、請求項1〜4のいずれか一項に記載の化合物の使用。
- ヒトまたは動物の身体に対して実施される診断方法において使用するための、請求項1〜4のいずれか一項に記載の化合物。
- 前記診断方法が、細胞の異常増殖により生じる、および/または悪化する症状を診断する方法である、請求項16に記載の使用のための化合物。
- インビトロ診断方法における、請求項1〜4のいずれか一項に記載の化合物の使用。
- 細胞の異常増殖により生じる、および/または悪化する症状の、光力学療法による治療のための薬剤の製造のための、請求項1〜4のいずれか一項に記載の化合物の使用。
- 細胞の異常増殖により生じる、および/または悪化する症状に罹患する、または罹患するリスクのあるヒトまたは動物患者を治療する方法であって、請求項1〜4のいずれか一項に記載の治療有効量の化合物を、前記患者に投与することと、前記化合物を含む前記患者の領域を、光力学療法の一部として露光することと、を含む、方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1215675.8A GB201215675D0 (en) | 2012-09-03 | 2012-09-03 | Compound |
GB1215675.8 | 2012-09-03 | ||
PCT/GB2013/052297 WO2014033477A1 (en) | 2012-09-03 | 2013-09-02 | Pyridinone compounds for use in photodynamic therapy |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2015526499A true JP2015526499A (ja) | 2015-09-10 |
JP2015526499A5 JP2015526499A5 (ja) | 2018-02-08 |
Family
ID=47075165
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015529127A Pending JP2015526499A (ja) | 2012-09-03 | 2013-09-02 | 光力学療法における使用のためのピリジノン化合物 |
Country Status (15)
Country | Link |
---|---|
US (1) | US9346758B2 (ja) |
EP (1) | EP2892881B1 (ja) |
JP (1) | JP2015526499A (ja) |
KR (1) | KR20150068374A (ja) |
CN (1) | CN104718190B (ja) |
AU (1) | AU2013308197B2 (ja) |
BR (1) | BR112015004732A2 (ja) |
CA (1) | CA2883754A1 (ja) |
GB (1) | GB201215675D0 (ja) |
IN (1) | IN2015DN02514A (ja) |
MX (1) | MX2015002705A (ja) |
RU (1) | RU2015111137A (ja) |
SG (1) | SG11201501604TA (ja) |
WO (1) | WO2014033477A1 (ja) |
ZA (1) | ZA201502153B (ja) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201215675D0 (en) | 2012-09-03 | 2012-10-17 | Univ Exeter | Compound |
EP3148528A1 (en) | 2014-06-02 | 2017-04-05 | University of Exeter | Combinations of a photosensitizer with a hydrogen sulfide donor, thioredoxin inhibitor or nitroxide for use in photodynamic therapy |
CN112062713B (zh) * | 2020-08-04 | 2023-03-31 | 浙江工业大学 | 具铁螯合性和pdt活性的ala-hpo杂合衍生物及其制备方法与应用 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH07500120A (ja) * | 1992-08-12 | 1995-01-05 | ビーティージー・インターナショナル・リミテッド | 薬剤組成物 |
JP2000510123A (ja) * | 1996-05-08 | 2000-08-08 | ニューヨーク・ブラッド・センター・インコーポレイテッド | ウイルス感染の治療方法 |
JP2004505105A (ja) * | 2000-07-27 | 2004-02-19 | フォトキュア エイエスエイ | 光化学治療における光増感剤としての5−アミノレブリン酸のエステル |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201215675D0 (en) | 2012-09-03 | 2012-10-17 | Univ Exeter | Compound |
-
2012
- 2012-09-03 GB GBGB1215675.8A patent/GB201215675D0/en not_active Ceased
-
2013
- 2013-09-02 CN CN201380053228.0A patent/CN104718190B/zh not_active Expired - Fee Related
- 2013-09-02 MX MX2015002705A patent/MX2015002705A/es unknown
- 2013-09-02 CA CA2883754A patent/CA2883754A1/en not_active Abandoned
- 2013-09-02 SG SG11201501604TA patent/SG11201501604TA/en unknown
- 2013-09-02 EP EP13771564.5A patent/EP2892881B1/en not_active Not-in-force
- 2013-09-02 IN IN2514DEN2015 patent/IN2015DN02514A/en unknown
- 2013-09-02 WO PCT/GB2013/052297 patent/WO2014033477A1/en active Application Filing
- 2013-09-02 US US14/425,385 patent/US9346758B2/en not_active Expired - Fee Related
- 2013-09-02 KR KR1020157008471A patent/KR20150068374A/ko not_active Application Discontinuation
- 2013-09-02 RU RU2015111137A patent/RU2015111137A/ru not_active Application Discontinuation
- 2013-09-02 AU AU2013308197A patent/AU2013308197B2/en not_active Ceased
- 2013-09-02 JP JP2015529127A patent/JP2015526499A/ja active Pending
- 2013-09-02 BR BR112015004732A patent/BR112015004732A2/pt not_active Application Discontinuation
-
2015
- 2015-03-30 ZA ZA2015/02153A patent/ZA201502153B/en unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH07500120A (ja) * | 1992-08-12 | 1995-01-05 | ビーティージー・インターナショナル・リミテッド | 薬剤組成物 |
JP2000510123A (ja) * | 1996-05-08 | 2000-08-08 | ニューヨーク・ブラッド・センター・インコーポレイテッド | ウイルス感染の治療方法 |
JP2004505105A (ja) * | 2000-07-27 | 2004-02-19 | フォトキュア エイエスエイ | 光化学治療における光増感剤としての5−アミノレブリン酸のエステル |
Non-Patent Citations (2)
Title |
---|
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, vol. 34, no. 6, JPN6017023385, 1999, pages 475 - 485, ISSN: 0003585909 * |
PHOTOCHEMISTRY AND PHOTOBIOLOGY, vol. Vol.86(5), JPN6017023387, 2010, pages 1154 - 1160, ISSN: 0003585910 * |
Also Published As
Publication number | Publication date |
---|---|
CN104718190A (zh) | 2015-06-17 |
RU2015111137A (ru) | 2016-10-20 |
GB201215675D0 (en) | 2012-10-17 |
US20150210642A1 (en) | 2015-07-30 |
CA2883754A1 (en) | 2014-03-06 |
IN2015DN02514A (ja) | 2015-09-11 |
MX2015002705A (es) | 2015-12-01 |
WO2014033477A1 (en) | 2014-03-06 |
ZA201502153B (en) | 2017-07-26 |
KR20150068374A (ko) | 2015-06-19 |
SG11201501604TA (en) | 2015-05-28 |
CN104718190B (zh) | 2017-03-08 |
BR112015004732A2 (pt) | 2018-04-17 |
AU2013308197A1 (en) | 2015-04-09 |
EP2892881A1 (en) | 2015-07-15 |
EP2892881B1 (en) | 2017-07-19 |
AU2013308197B2 (en) | 2018-02-01 |
US9346758B2 (en) | 2016-05-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1313695B1 (en) | Esters of 5-aminolevulinic acid as photosensitizing agents in photochemotherapy | |
EP3663286B1 (en) | Photosensitizer derivatives and application thereof | |
CA2480033C (en) | In vivo use of glutathionone s-transferase activated nitric oxide donors | |
US20050107471A1 (en) | New esters of 5-aminolevulinic acid and their use as photosensitizing compounds in photochemotherapy | |
CA3124820A1 (en) | Compositions and methods for modulating hair growth | |
CN110981870A (zh) | 基于pH和GSH双重响应的β-咔啉-环烯酮衍生物及其用途 | |
CN112010772A (zh) | 5-氨基酮戊酸及其衍生物的盐化合物和应用 | |
Li et al. | A new GSH-responsive prodrug of 5-aminolevulinic acid for photodiagnosis and photodynamic therapy of tumors | |
SA516371644B1 (ar) | مشتق إندولون به استبدال ببيرول وطريقة تحضيره والتركيبات المشتملة عليه واستخدامه | |
JP2015526499A (ja) | 光力学療法における使用のためのピリジノン化合物 | |
JP4162994B2 (ja) | 諸疾患状態の処置のための薬物に使用する化合物とその製造方法 | |
AU2002211725A1 (en) | Modified prodrug forms of AP/AMP | |
Wang et al. | Design, synthesis and biological evaluation of potent epidermal growth factor receptor tyrosine kinase (EGFR-TK) inhibitors against resistance mutation for lung cancer treatment | |
US20140100271A1 (en) | New 5-aminolevulinic acid prodrugs for use in photodynamic therapy and photodynamic diagnosis | |
EP1904060B1 (en) | Use of phthalocyanine derivates for the non-photodynamic treatment of diseases | |
EA016052B1 (ru) | N-α-(БЕНЗИЛОКСИКАРБОНИЛ)-L-γ-ГЛУТАМИЛ-3-[[2-[[БИС[БИС(2-ХЛОРЭТИЛ)АМИНО]ФОСФОНИЛ]ОКСИ]ЭТИЛ]СУЛЬФОНИЛ]-L-АЛАНИЛ-2(R)-ФЕНИЛГЛИЦИН ИЛИ ЕГО СОЛЬ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ ЭТО СОЕДИНЕНИЕ, ПРИМЕНЕНИЕ ЭТОГО СОЕДИНЕНИЯ ДЛЯ ЛЕЧЕНИЯ РАКА И СПОСОБ ЛЕЧЕНИЯ РАКА С ПОМОЩЬЮ ЭТОГО СОЕДИНЕНИЯ | |
Vena et al. | 5-Aminolevulinic acid ester–induced protoporphyrin IX in a murine melanoma cell line | |
EP4389827A1 (en) | Aminoglycoside-linked photosensitizers | |
Nelson | Development of Novel Monocarboxylate Transporter Inhibitors as Potential Anticancer Agents | |
WO2023023261A1 (en) | Radiofluorinated agents for pet imaging selectively targeting fibroblast activation protein | |
EP1615552A2 (en) | Sapphyrins and uses thereof | |
KR20060103530A (ko) | 종양 치료를 위한 제약학적 활성 성분으로 이용되는 프롤린유도체 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160831 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20160831 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20170622 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20170627 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20170925 |
|
A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20171225 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20180116 |